



6th ICTHIC Scientific Program

Friday, April 20th, 2012

2.00 - 2.15 pm **Congress Opening:** A. Falanga, F.R. Rickles, B. Brenner

2.15 - 4.30 pm **Plenary Session 1: Epidemiology and risk factors of venous thromboembolism**

Chairs: H.A. Liebman (USA), I. Pabinger (Austria)

PL01 Predictive potential of hemostatic biomarkers

C. Ay (Austria)

PL02 Update on thrombotic risk stratification

A. Khorana (USA)

PL03 Unsuspected PE in cancer patients

M. Monreal (Spain)

PL04 Cancer in pregnancy

B. Brenner (Israel)

OC01 Rate of venous thromboembolism by cancer type compared to the general population using multiple linked databases.

A.J. Walker, J. West, T.R. Card, C. Crooks, M.J. Grainge. (UK)

OC02 Thromboembolic complications in children with cancer: data from the italian registry of childhood thrombosis (RITI)

M.C.Putti, C. Gentilomo, E. Cavaliere, P. Saracco, P. Giordano, A.C. Molinari, M. Grassi, V. Buccella, A. Falanga, D. Sperli, P. Simioni e il Gruppo Italiano per il Registro Trombosi Infantile (GIRTI). (Italy)

5.00 - 7.15 pm **Plenary Session 2: Genomics and proteomics of the hemostatic system in cancer**

Chairs: M.-M. Samama (France), M. Cattaneo (Italy)

PL05 Genetic pathways linking hemostasis and cancer

J. Rak (Canada)

PL06 Platelet CLEC-2 in lymphangiogenesis and cancer metastasis

S.P. Watson (UK)

PL07 The platelet proteome

W.F. Bahou (USA)

PL08 Akt and Ras pathways and modulation of TF expression in glioblastoma

D. Brat (USA)

OC03 TrypsinogenIV, a new player in tumor angiogenesis.

C. Ghilardi, S. Figini, M. Lupi, R. Fruscio, R. Giavazzi and M.R. Bani. (Italy)

OC04 Novel functions of TFPI isoforms in breast cancer cells.

B. Stavik, G. Skretting, M. Tinholt, M. Sletten, P. Sandset, N. Iversen. (Norway)



7.30 pm **Second Simon Karpatkin Memorial Lecture**

Introduction F.R. Rickles (USA)

Hemostasis, innate immunity and malignancy

J.L. Degen (USA)

Saturday, April 21st, 2012

8.15 - 10.30 am **Plenary Session 3 : Bleeding complications in cancer patients**

Chairs: C.M. Kessler (USA), C. Velati (Italy)

PL09 Side effects of anti-angiogenic drugs

F. Rodeghiero (Italy)

PL10 Diagnosis and treatment of disseminated intravascular coagulation

C.-H. Toh (UK)

PL11 Transfusion issues in the cancer patient

A.B. Federici (Italy)

PL12 Acquired hemophilias in cancer

N.S. Key (USA)

OC05 Bleeding complications in patients with CKD and malignancy during anticoagulant treatment for venous thromboembolism.

J. Kooiman, P.L. den Exter, A. Gedik, J Hooijer, M.V. Huisman. (*The Netherlands*)

OC06 Evaluation of platelet function and thromboxane A2 production in aspirin-treated patients with essential thrombocythemia.

F. Lussana, E.A. Femia, M. Pugliano, G. Podda, C. Razzari, N. Maugeri, A. Lecchi, G. Motta, S. Caberlon, G. Gerli, M. Cattaneo. (*Italy*)

11.00 am - 1.15 pm **Plenary Session 4: Coagulation and cancer progression**

Chairs: M.B. Donati (Italy), R. Labianca (Italy)

PL13 The respective roles of TF isoforms in cancer

H.H. Versteeg (*Netherlands*)

PL14 Heparanase procoagulant activity

Y. Nadir (*Israel*)

PL15 Protein C and cancer

C.A. Spek (*Netherlands*)

PL16 Accounting for death as a competing risk in cancer VTE studies

J.I. Zwicker (USA)

OC07 Binding of anti-GRP78 autoantibodies to cell surface GRP78 promotes cancer progression by activating tissue factor procoagulant activity.

A.A. Al-Hashimi, F. Majeed, M. Gonzalez-Gronow, R.C. Austin. (*Canada, USA*)



OC08 Studying cell-microenvironment interactions in a microfluidics model of tumor microcirculation.

Z.N. Demou, V. Turitto. (USA)

2.15 - 4.30 pm **Plenary Session 5: Hematological disorders**

Chairs: G.H. Lyman (USA), R. Giavazzi (Italy)

PL17 Risk and management of thrombosis in multiple myeloma

F.W. Leebeek (Netherlands)

PL18 The role of JAK-2 inhibition

A. Rambaldi (Italy)

PL19 Splanchnic vein thrombosis: New risk factors and management

W. Ageno (Italy)

PL20 Heparin-induced thrombocytopenia in cancer

P.M. Sandset (Norway)

OC09 New potential markers of severe thrombo-hemorrhagic syndrome (THS) in acute promyelocytic leukemia (APL) patients: activated FVII-antithrombin complex (FVIIa-AT) and Tissue Factor (TF) mRNA

M. Marchetti, L. Russo, C.J. Tartari, B. Woodhams, E. Di Bona, A. Rambaldi, F. Lo Coco and A. Falanga. (Italy)

OC10 The pathogenesis of warfarin-associated venous limb ischemia and gangrene complicating cancer: clinical and laboratory parallels with heparin-induced thrombocytopenia (HIT).

T.E. Warkentin, R. Sarode, M.A. Johnston, M.A. Crowther. (USA)

5.00 - 7.15 pm **Plenary Session 6: Anticoagulants and cancer**

Chairs: S. Schulman (Canada), H.R. Büller (Netherlands)

PL21 New and old anticoagulants in cancer

G. Agnelli (Italy)

PL22 Guidelines for antithrombotics in cancer patients

D. Farge-Bancel (France)

PL23 Measurement of new oral anticoagulants

J. Harenberg (Germany)

PL24 LMWH and survival in lung cancer

S. Noble (UK)

OC11 The effect of aspirin on cancer mortality

T. Meade (UK)

OC12 New antithrombotic agents in the treatment of VTE; a subgroup analysis of the Phase III randomized clinical trials.



G.T. Gerotziakas, M.M. Samama, I. Elalamy. (*France*)

Sunday, April 22nd, 2012

8.15 - 10.30 am **Plenary Session 7: Platelets and vascular endothelium**

Chairs: C.W. Francis (USA), H. ten Cate (Netherlands)

PL25 The role of thrombomodulin in tumor growth and metastasis

N. Horowitz (*Israel*)

PL26 Endothelial cell activation markers in cancer

A.D. Blann (*UK*)

PL27 Novel functions of tissue factor in thrombosis and in cancer

W. Ruf (*USA*)

PL28 Microparticles in tumor progression

A. Falanga (*Italy*)

OC13 On the use of anti-platelet drugs to diminish both tumor growth and thrombosis.

R. Darbousset, S. Mezouar, R. Bonier, V. Sbarra, D. Farge-Bancel, C. Frère, C. Dubois, L. Panicot-Dubois (*France*).

OC14 Cellular origin and procoagulant activity of tissue factor-exposing microparticles in cancer patients.

A. Kleinjan, R.J. Berckmans, A.N. Böing, A. Sturk, H.R. Büller, P.W. Kamphuisen, R. Nieuwland (*The Netherlands*)

11.00 am - 1.15 pm **Plenary Session 8: Prevention and treatment of thrombosis**

Chairs: M.N. Levine (Canada), P. Prandoni (Italy)

PL29 Thromboprophylaxis in the cancer surgical patient

A.K. Kakkar (*UK*)

PL30 Thromboprophylaxis in non-surgical cancer patient

A.T. Cohen (*UK*)

PL31 Treatment of established thrombotic events

A.Y. Lee (*Canada*)

PL32 Overview of thrombosis and cancer survival

N. Kuderer (*USA*)

OC15 Use of vena cava filters in cancer patients in California.

R.H. White, A. Brunson, S. Murin, D.J. Tancredi, T. Wun. (*USA*)

OC16 Incidence of venous thromboembolism in patients undergoing laparoscopic surgery for colorectal cancer.

M.C. Vedovati, C. Becattini, F. Rondelli, M. Boncompagni, G. Camporese, R. Balzarotti, E. Mariani, O. Flamini, G. Natalini, G. Agnelli. (*Italy*)